ClinicalTrials.gg
CompletedNCT00606229Updated Mar 13, 2014Results posted

A Multicenter Investigative Study of the Safety and Efficacy of Long-term Administration of Aripiprazole in Combination With Mood Stabilizer for the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode

A Phase 3 interventional study of Aripiprazole in Bipolar I Disorder, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 5 sites in Japan. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2014-03-13.

Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
41
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

To assess the safety and efficacy of long-term administration of aripiprazole in combination with mood stabilizer (lithium or valproate) in an unblinded manner in patients with Bipolar I Disorder experiencing a manic or mixed episode

02

Conditions studied

  • Bipolar I Disorder
03

In context

Lead sponsor

Otsuka Pharmaceutical Co., Ltd. is the lead sponsor of 143 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Trial subjects will be men and women of age 18 or above and below the age of 65 who will not be turning 65 during the trial.
  • Patients have the ability to understand and to provide to the examination, observation, and evaluation processes specified in this protocol, and have signed the informed consent form based on a full understanding of the trial.
  • Patients who meet criteria for manic or mixed episodes and have been diagnosed as having "296.4x Bipolar I Disorder in which the most recent episode was manic" or "296.6x Bipolar I Disorder in which the most recent episode was mixed"
  • Patients with a YMRS total score of 16 or more

Exclusion criteria

Exclusion Criteria:

  • Patients presenting with a clinical picture and/or history that is consistent with a diagnosis of:

    • Delirium, dementia, amnestic disorder, or other cognitive disorders
    • Schizophrenia or other psychotic disorder
    • Personality disorder
  • Patients experiencing their first manic or mixed episode
  • Patients whose current manic episode has lasted for more than 4 weeks
  • Patients with psychotic symptoms that are clearly due to another general medical condition or direct physiological effects of a substance
  • Patients who have met DSM-IV-TR criteria for a substance-related disorder within 3 months (90 days) prior to (excluding caffeine- and nicotine-related disorders, but including abuse of benzodiazepines)
  • Patients who have received ECT treatment within 8 weeks prior to informed consent
  • Patients who are expected to require administration of ultrashort-acting or short-acting benzodiazepine receptor agonist hypnotics and antianxiety drugs (See (1) of 4.2.2) at doses exceeding the equivalent of 15 mg/day of diazepam (Only for those patients using such drugs)
  • Patients at significant risk of developing a severe adverse event. Patients who have a medical condition that would interfere with assessments of safety or efficacy during the course of the trial, or who have a history of such a condition.
  • Patients who have received any of the following treatments during the screening period

    • Reserpine
    • Levodopa, dopamine receptor stimulants
    • Monoamine oxidase inhibitors
    • Psychostimulants
    • Thyroid hormones, antithyroid drugs
    • (other than topical preparations)
    • Adrenaline
    • All other or unapproved agents
    • ECT
    • Light therapy
  • Patients judged to have a diabetic blood glucose level (judgment based on use of a self-monitoring blood glucose meter permissible), or patients whose is 6.5% or higher
  • Patients with a history or a complication of diabetes
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
41 participants (actual)

Study arms

  • Experimental
    1

    Drug: Aripiprazole

Interventions

06

What researchers measure

Primary outcomes

  1. Young Mania Rating Scale (YMRS)

    Mean change from baseline (Day 1) to endpoint in the YMRS total score YMRS is composed of 11 evaluation items with 5 rating levels each. Items rated on a scale of 0 to 4 (comprising 5 rating levels of one point each) are 1) elevated mood, 2) increased motor activity/energy, 3) sexual interest, 4) sleep, 7) language-thought disorder, 10) appearance, and 11) insight. Items rated on a scale of 0 to 8 (comprising 5 rating levels of two points each) are 5) irritability, 6) speech (rate and amount), 8) content, and 9) disruptive-aggressive behavior. Total score range is 0 to 60, and the higher value represents worsen.

    Time frame: Day 1 and Day 168 or time of discontinuation

Secondary outcomes

  1. Clinical Global Impression - Bipolar Version (CGI-BP) Sevirity of Illness Score (Mania)

    Mean change from baseline (Day 1) to endpoint in Clinical Global Impression -Bipolar Version (CGI-BP) severity of illness score (mania) The severity of manic symptoms on a scale of 1 (normal, not ill) to 7 (very severely ill)

    Time frame: Day 1 and Daty 168 or time of discontinuation

07

Results

Posted Mar 13, 2014

Participant flow

Participant flow — Overall Study
MilestoneAripiprazole
Started41
Completed19
Not completed22
Withdrew: Adverse event11
Withdrew: Lack of efficacy1
Withdrew: Withdrawal by subject4
Withdrew: Does not meet inclusion criterion 1-34
Withdrew: Change of residence or other commitments2

Outcome measures

PrimaryYoung Mania Rating Scale (YMRS)

Mean change from baseline (Day 1) to endpoint in the YMRS total score YMRS is composed of 11 evaluation items with 5 rating levels each. Items rated on a scale of 0 to 4 (comprising 5 rating levels of one point each) are 1) elevated mood, 2) increased motor activity/energy, 3) sexual interest, 4) sleep, 7) language-thought disorder, 10) appearance, and 11) insight. Items rated on a scale of 0 to 8 (comprising 5 rating levels of two points each) are 5) irritability, 6) speech (rate and amount), 8) content, and 9) disruptive-aggressive behavior. Total score range is 0 to 60, and the higher value represents worsen.

Time frame:
Day 1 and Day 168 or time of discontinuation
Reported as:
Mean · scores on a scale
Young Mania Rating Scale (YMRS)
scores on a scaleAripiprazole
Young Mania Rating Scale (YMRS)-18.8 ± 9.86
SecondaryClinical Global Impression - Bipolar Version (CGI-BP) Sevirity of Illness Score (Mania)

Mean change from baseline (Day 1) to endpoint in Clinical Global Impression -Bipolar Version (CGI-BP) severity of illness score (mania) The severity of manic symptoms on a scale of 1 (normal, not ill) to 7 (very severely ill)

Time frame:
Day 1 and Daty 168 or time of discontinuation
Reported as:
Mean · scores on a scale
Clinical Global Impression - Bipolar Version (CGI-BP) Sevirity of Illness Score (Mania)
scores on a scaleAripiprazole
Clinical Global Impression - Bipolar Version (CGI-BP) Sevirity of Illness Score (Mania)-2.6 ± 1.50

Adverse events

Collected over 24 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Aripiprazole—4/41 (9.8%)35/41 (85.4%)
Most frequent serious events
Most frequent serious events
EventAripiprazole
Bipolar I DisorderPsychiatric disorders2/41
RhabdomyolysisMusculoskeletal and connective tissue disorders1/41
AkathisiaNervous system disorders1/41
Most frequent other events
Showing 10 of 18
Most frequent other events
EventAripiprazole
AkathisiaNervous system disorders18/41
SomnolenceNervous system disorders14/41
NauseaGastrointestinal disorders9/41
TremorNervous system disorders9/41
Blood Creatine Phosphokinase IncreasedInvestigations7/41
Weight IncreasedInvestigations7/41
Salivary HypersecretionGastrointestinal disorders6/41
NasopharyngitisInfections and infestations6/41
BradykinesiaNervous system disorders6/41
InsomniaPsychiatric disorders6/41

Baseline characteristics

Results obtained from the LOCF dataset of 40 subjects of the Full Analysis Set (FAS) (excluding 1 subject whose post-dose data of efficacy endpoint were not available from the 41 treated subjects)

Age, Continuous
Age, Continuous(years)Aripiprazole
Mean40.4 ± 10.89
Age, Categorical
Age, Categorical(Participants)Aripiprazole
<=18 years0
Between 18 and 65 years40
>=65 years0
Sex: Female, Male
Sex: Female, Male(Participants)Aripiprazole
Female18
Male22
Region of Enrollment
Region of Enrollment(participants)Aripiprazole
Japan40
08

Study locations

5 sites
  • Chugoku region, Japan
  • Hokuriku region, Japan
  • Kanto region, Japan
  • Kinki region, Japan
  • Shikoku region, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2008, a primary completion of Nov 2010 and a completion of Nov 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2014, 3 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 19, 2008
First posted
Feb 1, 2008
Start
Jan 2008
Primary completionActual
Nov 2010
CompletionActual
Nov 2010
Results first posted
Mar 13, 2014
Last update
Mar 13, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00606229
Responsible party
Sponsor
First posted
Feb 1, 2008
Start date
Jan 2008
Primary completion
Nov 2010
Completion
Nov 2010
Results posted
Mar 13, 2014
Last update
Mar 13, 2014

Study contacts

Katsuhisa Saito
study director · Department of Clinical Research and Development, Division of New Product Evaluation and Development

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aripiprazole

Start the discussion